Cognition Therapeutics (CGTX)

• Market cap: $26.2M
• 1 day: -0.62%
• 5 days: 32.29%
• 1 month: 43.20%
• 3 months: 8.71%
• 6 months: -69.11%
• Year to date: -67.52%
• 1 year: -62.27%
• 5 years: -95.07%
• 10 years: -95.07%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

2.66% less ownership

Funds ownership: 13.26% [Q2] → 10.6% (-2.66%) [Q3]

13% less funds holding

Funds holding: 46 [Q2] → 40 (-6) [Q3]

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

78% less capital invested

Capital invested by funds: $8.82M [Q2] → $1.96M (-$6.86M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 138% upside
• Avg. target: $6.17 879% upside
• High target: $11 1,646% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

B. Riley Securities Mayank Mamtani 35% 1-year accuracy 8 / 23 met price target	138% upside $1.50	Buy Upgraded	19 Dec 2024
Chardan Capital Daniil Gataulin 25% 1-year accuracy 8 / 32 met price target	1,646% upside $11	Buy Maintained	19 Dec 2024
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target	852% upside $6	Buy Maintained	19 Dec 2024